Co-torrefaction of microalgae and lignocellulosic biomass was evaluated as a method to process microalgae sludge produced from various effluents and to obtain biochars with suitable properties for energy or material valorization. The influence of four independent variables on biochar yield and properties was evaluated by a set of experiments defined by response surface methodology (RSM). The biochars were characterized for proximate and ultimate composition, HHV, and methylene blue adsorption capacity. HHV of the biochars was positively correlated with carbonization temperature, residence time, and lignocellulosic biomass content in the feed. Co-torrefaction conditions that led to a higher yield of biochar (76.5%) with good calorific value (17.4 MJ Kg⁻¹) were 250 °C, 60 min of residence time, 5% feed moisture, and 50% lignocellulosic biomass. The energy efficiency of the process was higher for lower temperatures (92.6%) but decreased abruptly with the increase of the moisture content of the feed mixture (16.9 to 57.3% for 70% moisture). Biochars produced using algal biomass grown in contaminated effluents presented high ash content and low calorific value. Dye removal efficiency by the produced biochars was tested, reaching 95% methylene blue adsorption capacity for the biochars produced with the least severe torrefaction conditions.

Background: Diffuse low-grade gliomas (DLGGs) are rare and incurable tumors. Whereas maximal safe, functional-based surgical resection is the first-line treatment, the timing and choice of further treatments (chemotherapy, radiation therapy, or combined treatments) remain controversial. Methods: An online survey on the management of DLGG patients was sent to 28 expert centers from the European Low-Grade Glioma Network (ELGGN) in May 2015. It contained 40 specific questions addressing the modalities of use of chemotherapy in these patients. Results: The survey demonstrated a significant heterogeneity in practice regarding the initial management of DLGG patients and the use of chemotherapy. Interestingly, radiation therapy combined with the procarbazine, CCNU (lomustine), and vincristine regimen has not imposed itself as the gold-standard treatment after surgery, despite the results of the Radiation Therapy Oncology Group 9802 study. Temozolomide is largely used as first-line treatment after surgical resection for high-risk DLGG patients, or at progression. Conclusions: The heterogeneity in the management of patients with DLGG demonstrates that many questions regarding the postoperative strategy and the use of chemotherapy remain unanswered. Our survey reveals a high recruitment potential within the ELGGN for retrospective or prospective studies to generate new data regarding these issues.